Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3641 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Medivation begins Phase II Dimebon trial

Medivation has expanded patient enrollment in the trial by 20% – to 90 patients – in order to enhance the ability to detect differences between Dimebon and placebo.

Shire’s new ADHD medication now available

In a clinical study, Vyvanse provided consistent ADHD symptom control throughout the day based upon parent reports in the morning (approximately 10am), afternoon (approximately 2pm), and early evening